But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

From an enrollment of more than 5 million, crude prevalence of autosomal dominant polycystic kidney disease was 67.3 per 100,000 persons. Prevalence was lowest for Native American and Alaska ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD: Basel Friday, May 2, 2025, 14:00 Hrs [IST] Novartis annou ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Regulus Therapeutics Inc. CEO Jay Hagan told investors in a January call the company had no interest in “simply out-licensing” rights to lead candidate farabursen, an oligonucleotide targeting ...

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...